SGLT2 inhibitors are FDA-approved drugs prescribed to lower blood sugar in adults with type-2 diabetes. However, the effect of SGLT2 inhibitors on cardiovascular and kidney outcomes is not known. This study aims to assess the cardiovascular and kidney outcomes in patients taking SGLT2 inhibitors for type-2 diabetes.

This systematic review and meta-analysis of PubMed studies included data from 6 trials examining the CV and kidney outcomes on patients with type-2 diabetes taking SGLT2 inhibitors. The primary outcomes of the study were a composite of major adverse CV events of stroke, myocardial infarction, or CV death, the composite of hospitalization for heart failure, and kidney composite outcomes.

The overall findings suggested that the use of SGLT2 inhibitors was associated with a reduced risk of major adverse CVD events (hazard ratio 0.90) and kidney outcomes (HR 0.62). The associated risk reductio of hospitalization due to heart failure was consistent across all trials. However, significant heterogeneity of associations with outcome was reported for cardiovascular death. The presence of ACVD wasn’t associated with any outcomes.

The research concluded that SGLT2 inhibitors were associated with a reduced risk of major adverse cardiovascular and kidney events, and there was significant heterogeneity in association with CV death.